Biopharmaceutical company developing treatments for cardiopulmonary diseases.
Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing treatments that improve the lives of patients with rare cardiopulmonary diseases in the United States. The company's primary focus is on advancing AV-101, a dry powder inhaled formulation of imatinib, which is currently undergoing Phase 2b/Phase 3 clinical trials for the treatment of pulmonary arterial hypertension. This innovative approach aims to provide a more effective and convenient therapy for patients suffering from this serious condition.
Incorporated in 2018 and headquartered in Waltham, Massachusetts, Aerovate Therapeutics leverages cutting-edge research and development to create novel therapies for underserved patient populations. The company's mission is to bring transformative treatments to market, addressing significant unmet medical needs in the field of cardiopulmonary diseases.
Aerovate's team comprises experienced professionals with extensive expertise in drug development, particularly in the areas of pulmonary and cardiovascular diseases. Their collective experience and dedication drive the company's progress in developing AV-101 and exploring additional therapeutic opportunities within the cardiopulmonary space.
By focusing on innovative drug delivery systems and novel therapeutic targets, Aerovate Therapeutics aims to revolutionize the treatment landscape for rare cardiopulmonary diseases. The company's commitment to scientific excellence and patient-centered care positions it at the forefront of biopharmaceutical innovation, striving to enhance the quality of life for patients worldwide.